4DMedical Limited (ASX:4DX) Secures New Industry Contracts and Gains Congressional Recognition
4DMedical Limited (ASX:4DX) has secured two new industry contracts for its advanced lung imaging technology and was highlighted in US Congressional testimony on VA Healthcare Modernisation, enhancing its position in the respiratory health sector.
New Industry Contracts
4DMedical has entered into two significant contracts. The first is with SMS Biotech for their Phase 1 trial of stem cell therapy for COPD treatment. This contract is valued at US$40k for 42 quantitative assessments at Cabrini Health. The second contract is with a multinational lung device developer to support clinical trials for a novel lung implantable device, demonstrating the versatility and growing adoption of 4DMedical’s technology in respiratory health.
Congressional Recognition
4DMedical’s technology was highlighted by Philips during Congressional Testimony on VA Healthcare Modernization. Jeff DiLullo, Executive Vice President and Chief Executive Officer of Philips North America, praised the company’s FDA-cleared cardiopulmonary software for transforming standard CT imaging into detailed four-dimensional images, improving pulmonary function assessment for veterans.
Executive Comments
Andreas Fouras, MD/CEO and Founder of 4DMedical, stated, “Our partnership with SMS Biotech, and other industry innovation leaders, highlights the growing demand for 4DMedical’s imaging technology. By providing precise structural imaging and rich functional insights, we are accelerating success for our industry partners in their quest to bring novel and powerful treatments to market.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.